Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.

[1]  L. J. Lee,et al.  Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[2]  X. Jing,et al.  Size-dependent biodistribution and antitumor efficacy of polymer micelle drug delivery systems. , 2013, Journal of materials chemistry. B.

[3]  D. Rockey,et al.  Altered Mental Status in Cirrhosis , 2013, Journal of Investigative Medicine.

[4]  Isobel Leake.  Liver: Size matters: effects of reduced paracetamol pack sizes in England and Wales , 2013, Nature Reviews Gastroenterology &Hepatology.

[5]  N. Svrzikapa,et al.  First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. , 2013, Cancer discovery.

[6]  K. Ghoshal,et al.  Lipid nanoparticles for hepatic delivery of small interfering RNA. , 2012, Biomaterials.

[7]  Hsien-Da Huang,et al.  MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. , 2012, The Journal of clinical investigation.

[8]  M. Caligiuri,et al.  Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. , 2012, The Journal of clinical investigation.

[9]  Bo Yu,et al.  SPANosomes as delivery vehicles for small interfering RNA (siRNA). , 2012, Molecular pharmaceutics.

[10]  J. Yano,et al.  Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA. , 2011, Biological & pharmaceutical bulletin.

[11]  Bo Yu,et al.  MicroRNA delivery by cationic lipoplexes for lung cancer therapy. , 2011, Molecular pharmaceutics.

[12]  B. Polisky,et al.  An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. , 2011, Molecular Therapy.

[13]  L. J. Lee,et al.  Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery. , 2011, Anticancer research.

[14]  S. Fesik,et al.  A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors. , 2011, RNA.

[15]  Daniel A. Balazs,et al.  Liposomes for Use in Gene Delivery , 2010, Journal of drug delivery.

[16]  Zhan Yuin Ong,et al.  Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases , 2010 .

[17]  Andrew D. Miller,et al.  DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[19]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[20]  Kathryn A. Whitehead,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[21]  R. Langer,et al.  Lipid‐based nanotherapeutics for siRNA delivery , 2010, Journal of internal medicine.

[22]  K. Ghoshal,et al.  TGFβ mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3 , 2009, Oncogene.

[23]  A. Judge,et al.  Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. , 2009, The Journal of clinical investigation.

[24]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[25]  Jen-Leih Wu,et al.  miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. , 2008, Biochemical and biophysical research communications.

[26]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[27]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[28]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[29]  J. Heyes,et al.  Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[30]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[31]  V. Vlassov,et al.  Cationic lipid-DNA complexes-lipoplexes-for gene transfer and therapy. , 2002, Bioelectrochemistry.

[32]  Ana Ivelisse Avilés,et al.  Linear Mixed Models for Longitudinal Data , 2001, Technometrics.

[33]  Y. Maitani,et al.  MODIFIED ETHANOL INJECTION METHOD FOR LIPOSOMES CONTAINING β-SITOSTEROL β-D-GLUCOSIDE , 2001, Journal of liposome research.

[34]  Guisheng Zhang,et al.  Structural basis of DOTMA for its high intravenous transfection activity in mouse , 2000, Gene Therapy.

[35]  J. L. Nieva,et al.  Induction of aggregation and fusion of cholesterol-containing membrane vesicles by an anti-cholesterol monoclonal antibody. , 2000, Journal of lipid research.

[36]  T Salditt,et al.  An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. , 1998, Science.

[37]  F. Szoka,et al.  Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. , 1998, Biochimica et biophysica acta.

[38]  R. Kumar,et al.  Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. , 1994, The Journal of biological chemistry.

[39]  K. Maruyama,et al.  Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). , 1992, Biochimica et biophysica acta.

[40]  N. Dock.  The ABC's of viral hepatitis , 1991 .

[41]  M. van Galen,et al.  Intrahepatic distribution of small unilamellar liposomes as a function of liposomal lipid composition. , 1986, Biochimica et biophysica acta.

[42]  B. de Kruyff,et al.  The function of sterols in membranes. , 1976, Biochimica et biophysica acta.

[43]  George A. Calin,et al.  RNA interference in the clinic: challenges and future directions , 2011, Nature Reviews Cancer.

[44]  P. Ruck,et al.  Bcl-2 gene silencing in pediatric epithelial liver tumors. , 2008, The Journal of surgical research.

[45]  S. Krugman.  The Gordon Wilson Lecture. The ABC's of viral hepatitis. , 1992, Transactions of the American Clinical and Climatological Association.

[46]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .